NRP1 and renal carcinoma: Interestingly, emerging evidence suggests that the retained expression of angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), and neurolipin 1 (NRP1) on the renal cancer cell could increase tumor immunogenicity and promote a cytolytic effect [28,29].